Clinical Efficacy of Stent-balloon-stent (SBS) Technique in the Treatment of Coronary Bifurcation Lesions
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jin Gao, BD
- Phone Number: +86 371 58681130
- Email: gao-jin@foxmail.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China
- Recruiting
- Fuwai Central China Cardiovascular Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- There is evidence of myocardial ischemia, such as coronary angiography, including patients with stable angina pectoris, unstable angina pectoris, asymptomatic myocardial ischemia and acute myocardial infarction (> 24 hours).
- All bifurcation lesions were Medina 1, 1, 1 or 0, 1, 1 with reference vessel diameter (RVD) in the SB ≥2.5 mm by visual estimation and had to meet DEFINITION criteria of complex bifurcations
- Patients who can tolerate long-term antiplatelet therapy
- None of the vessels related to bifurcation lesions have received stent surgery
- Patients who agree and sign an informed consent form
Exclusion Criteria:
- Patients who are unwilling to sign the relevant informed consent form
- Patients with severe surgical contraindications
- Life expectancy of patients is less than 12 months
- Patients who have previously undergone stent implantation or surgical coronary artery bypass grafting for related lesions
- Patients with severe hepatorenal insufficiency
- Heart failure patients with NYHA grade ≥ Ⅲ
- Patients who are scheduled for surgery requiring antiplatelet medication interruption within 6 months
- Patients who need chronic oral anticoagulation
- Any clinical condition of the patient may interfere with medication compliance or long-term follow-up
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Stent-balloon-stent (SBS) technique
Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique.
The procedure of this technique is to implant the stent into the side branch at the 1~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel.
The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
|
Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique.
The procedure of this technique is to implant the stent into the side branch at the 1~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel.
The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Target lesion failure rate
Time Frame: 3-12 months
|
cardiac death
|
3-12 months
|
|
Target lesion failure rate
Time Frame: 6-12 months
|
target vessel myocardial infarction (TVMI)
|
6-12 months
|
|
Target lesion failure rate
Time Frame: 6-12 months
|
clinically driven target lesion revascularization (TLR)
|
6-12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
minimum lumen area and lumen stenosis rate
Time Frame: 6-12months
|
minimum lumen area and lumen stenosis rate
|
6-12months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Xianpei Wang, MD, FF
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HenanICE2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.